A Bill Template to Make Nebulized Budesonide and Nebulizer Machines Over-the-Counter

This bill template is designed for legislators at the local, state, or federal level to use in drafting legislation that authorizes the over-the-counter (OTC) sale of nebulized budesonide and nebulizer machines. By expanding public access to this well-documented and effective respiratory treatment, such legislation would help ensure timely and affordable care for individuals in need. Budesonide, a corticosteroid with a strong safety profile, has demonstrated significant efficacy in mitigating severe respiratory symptoms, including those associated with COVID-19, as evidenced by multiple clinical trials such as the Oxford STOIC and PRINCIPLE trials. Key provisions of the bill include: The removal of prescription requirements for nebulized budesonide (respules) and nebulizer machines, enabling direct consumer access. Regulatory adjustments to align with existing OTC availability of budesonide in nasal spray form. Statutory protections for pharmacists, retailers, and manufacturers against liability when acting in compliance with the law. State Board of Pharmacy oversight to ensure proper labeling and consumer education on usage. The bill is supported by extensive clinical data, including research published in The Lancet Respiratory Medicine, Annals of Internal Medicine, and Science, all of which highlight the benefits of inhaled budesonide in reducing hospitalization, improving recovery times, and mitigating cytokine-driven respiratory distress. Furthermore, international health agencies, including the World Health Organization (WHO) and the U.K. Department of Health, recognize budesonide as an essential medicine for respiratory conditions. Given the strong safety profile of nebulized budesonide, its efficacy in treating acute respiratory distress, and the demonstrated public health benefits during the COVID-19 pandemic, this bill aims to eliminate unnecessary barriers to access. By allowing OTC sales of nebulized budesonide and nebulizer machines, this legislation prioritizes patient autonomy, ensures timely treatment availability, and supports a proactive approach to respiratory health management. For full details, references, and supporting clinical studies, please refer to the complete bill text. Contact: [email protected]

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-03-06
DOI
https://doi.org/10.5281/zenodo.14984569
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Bill Template to Make Nebulized Budesonide and Nebulizer Machines Over-the-Counter

Zenodo (CERN European Organization for Nuclear Research)
Inhalation and Respiratory Drug Delivery
article

A Bill Template to Make Nebulized Budesonide and Nebulizer Machines Over-the-Counter

article en

Abstract

This bill template is designed for legislators at the local, state, or federal level to use in drafting legislation that authorizes the over-the-counter (OTC) sale of nebulized budesonide and nebulizer machines. By expanding public access to this well-documented and effective respiratory treatment, such legislation would help ensure timely and affordable care for individuals in need. Budesonide, a corticosteroid with a strong safety profile, has demonstrated significant efficacy in mitigating severe respiratory symptoms, including those associated with COVID-19, as evidenced by multiple clinical trials such as the Oxford STOIC and PRINCIPLE trials. Key provisions of the bill include: The removal of prescription requirements for nebulized budesonide (respules) and nebulizer machines, enabling direct consumer access. Regulatory adjustments to align with existing OTC availability of budesonide in nasal spray form. Statutory protections for pharmacists, retailers, and manufacturers against liability when acting in compliance with the law. State Board of Pharmacy oversight to ensure proper labeling and consumer education on usage. The bill is supported by extensive clinical data, including research published in The Lancet Respiratory Medicine, Annals of Internal Medicine, and Science, all of which highlight the benefits of inhaled budesonide in reducing hospitalization, improving recovery times, and mitigating cytokine-driven respiratory distress. Furthermore, international health agencies, including the World Health Organization (WHO) and the U.K. Department of Health, recognize budesonide as an essential medicine for respiratory conditions. Given the strong safety profile of nebulized budesonide, its efficacy in treating acute respiratory distress, and the demonstrated public health benefits during the COVID-19 pandemic, this bill aims to eliminate unnecessary barriers to access. By allowing OTC sales of nebulized budesonide and nebulizer machines, this legislation prioritizes patient autonomy, ensures timely treatment availability, and supports a proactive approach to respiratory health management. For full details, references, and supporting clinical studies, please refer to the complete bill text. Contact: [email protected]

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 36%
Inhalation and Respiratory Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.